House dust mite immunotherapy in respiratory allergies

Respiratory diseases constitute a significant public health concern, with allergic rhinitis representing the most prevalent manifestation of allergic disorders. The inflammatory process in allergic rhinitis is driven by complex pathophysiological mechanisms, and a thorough understanding of these mechanisms may facilitate the identification of novel therapeutic targets and the enhancement of existing treatment strategies. Allergen-specific immunotherapy remains the only intervention capable of modifying the underlying pathophysiology of IgE-mediated allergic diseases, such as asthma and allergic rhinitis. Evidence from observational and randomized clinical trials demonstrates that immunotherapy offers superior symptom control and reduces the need for maintenance medication in patients with allergic rhinoconjunctivitis and/or asthma. Mite allergen immunotherapy should be administered concomitantly with conventional pharmacotherapy for a minimum of three years, with clinical benefits persisting for several years following treatment discontinuation. Furthermore, it may prevent the onset of new sensitizations and hinder the progression from allergic rhinitis to asthma in pediatric populations. The efficacy of immunotherapy is contingent upon the appropriate selection of candidates, the quality of allergen extracts employed, patient adherence, and the duration of treatment.